NEW YORK – Roche said this week that the US Food and Drug Administration has granted the company's Elecsys Galad score breakthrough device designation. The algorithmic score combines a patient gender’s and age, and the results of Roche’s Elecsys test for biomarkers AFP, AFP-L3, and PIVKA-II to aid in the diagnosis of early-stage hepatocellular carcinoma.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.
Don't have a 360Dx or GenomeWeb account?
Register for Free.